← Back to Search

CAR T-cell Therapy

CAR T-cell Therapy for Multiple Sclerosis

Phase 1

Recruiting

Led By Jeffrey Dunn, MD

Research Sponsored by Stanford University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patient is ≥ 18 years old, and ≤55 years of age, at time of screening visit

Progressive MS by 2014 Lublin MS phenotypic criteria

Must not have

History of neuromyelitis optica spectrum disorder (NMOSD) or MOG antibody associated disease (MOGAD)

Impaired cardiac function or clinically significant cardiac disease

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 months

Awards & highlights

Summary

This trial will use gene therapy to treat MS, testing if a modified immune cell can stop or slow the progression of the disease.

Who is the study for?

This trial is for adults aged 18-55 with progressive forms of Multiple Sclerosis, as per the McDonald and Lublin criteria. Participants must have certain antibody levels, normal organ function, no recent investigational drugs or specific treatments, and agree to contraception if applicable.

What is being tested?

The study tests KYV-101 anti-CD19 CAR-T cell therapy following a standard lymphodepletion regimen in patients with non-relapsing and progressive MS. It aims to evaluate the safety and effectiveness of this innovative treatment approach.

What are the potential side effects?

Potential side effects may include immune system reactions, infusion-related responses, changes in blood counts leading to increased infection risk or bleeding problems, fatigue, and possible impacts on liver or kidney function.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 18 and 55 years old.

Select...

My MS is getting worse according to the 2014 Lublin criteria.

Select...

I have antibodies against the Epstein-Barr virus.

Select...

My blood tests show normal immune and marrow function.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have a history of NMOSD or MOGAD.

Select...

I have heart problems that affect my daily activities.

Select...

I have had my spleen removed.

Select...

I have a history of moderate or severe asthma or COPD.

Select...

I have a heart valve condition.

Select...

My kidneys do not work well.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Secondary study objectives

Incidence of adverse events (AEs) including clinical tolerance and laboratory abnormalities

To characterize the pharmacodynamics (PD)

To characterize the pharmacokinetics (PK)

+1 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: KYV-101 CAR-T cells with lymphodepletion conditioningExperimental Treatment2 Interventions

Dosing with KYV-101 CAR T cells

0 / 10Eligibility criteria met

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor

2,448 Previous Clinical Trials

17,492,382 Total Patients Enrolled

3 Trials studying Multiple Sclerosis

197 Patients Enrolled for Multiple Sclerosis

Kyverna TherapeuticsIndustry Sponsor

8 Previous Clinical Trials

272 Total Patients Enrolled

2 Trials studying Multiple Sclerosis

130 Patients Enrolled for Multiple Sclerosis

Jeffrey Dunn, MDPrincipal InvestigatorStanford University

~8 spots leftby Jun 2027

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.